3B Future Health Fund
Venture capitalMonaco · Seed–Late Stage · 10 people tracked
Investment thesis
3B Future Health Fund backs early-stage biotech companies developing new therapies in areas of high unmet medical need, with a focus on oncology and rare disease therapeutics. Founded in 2016 by Riccardo Braglia and initially tied to Helsinn, the fund combines pharmaceutical industry know-how with a diversified, experienced drug development team. It supports promising projects from preclinical stages through clinical development, drawing on its network and expertise to advance life-changing treatments for patients with cancer or rare diseases. The fund has invested in 20+ start-ups and recorded an early exit with the EUR 425 million acquisition of AMAL Therapeutics in 2019; its second vehicle, Fund II, continues the same strategy.
Source: firm website, verified Aug 2, 2026.
Team · 10 people
from the firm's websiteThird-generation drug development professional and Executive Chairman of Helsinn who launched the 3B Future Health Fund in 2016.
Investments · 8 tracked
founders shown can be your intro pathFrequently asked questions
- What stage does 3B Future Health Fund invest at?
- 3B Future Health Fund invests at the Seed, Series A, Late Stage stages.
- What is 3B Future Health Fund's typical check size?
- 3B Future Health Fund typically writes checks of $12M.
- What sectors does 3B Future Health Fund focus on?
- 3B Future Health Fund focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is 3B Future Health Fund located?
- 3B Future Health Fund is headquartered in Monaco, MC.
Similar investors
Amadeus Capital Partners is a technology investor. It held a first close of $75M on its Amadeus IV Digital Prosperity Fund, focused on late-stage venture and growth companies building online and mobile services for emerging-market middle classes.
B Capital Group is a multistage venture capital firm that invests from seed to late stage, offering value-added support to founders in partnership with management consulting firm BCG.
Capricorn Venture Partners is a Belgium-based venture capital firm managing several funds across health, cleantech, digital, and fusion sectors, accepting pitches from companies raising capital.
DCVC (Data Collective) is a deep tech venture capital firm backing entrepreneurs using computational approaches to solve large real-world problems across many industries. It operates six flagship funds plus DCVC Bio, spanning 13 funds to date.
GV, originally launched as Google Ventures in 2009, is an independent venture capital firm with Alphabet as its sole limited partner. It invests from seed to growth stages across technology and life sciences and supports founders with operating partners and access to Google and Alphabet resources.